DA 4505
Alternative Names: DA-4505Latest Information Update: 12 Mar 2024
At a glance
- Originator Dong-A ST
- Class Antineoplastics; Small molecules
- Mechanism of Action Aryl hydrocarbon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Mar 2024 Dong-A ST plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in March 2024 (NCT06293651)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2023 Preclinical trials in Cancer in South Korea (PO), prior to April 2023